NOVO NORDISK A/S-B reported Q1 adjusted operating profit of 32.86 billion Danish crowns, beating analyst forecasts of 28.74 billion crowns. The Denmark drugmaker narrowed its 2026 sales and profit decline outlook to a range of 4% to 12%. Investors are weighing whether new oral weight-loss pills can offset pricing pressure and competition in the United States.

Wegovy Pill Targets Recovery Amid Pricing Pressure